Oncotarget:A Multidisciplinary Journal With Scientific Reseach On Cancer And More
Oncotarget is a weekly, online, open-access, peer-reviewed medical journal that provides in-depth articles, papers and research information on all areas of oncology. Founded in 2010, it is published by Impact Journals. Noted cancer researchers and professors Mikhail Blagosklonny and Andrei V. Gudkov are Oncotarget’s editors-in-chief. Abstracted and indexed in Scopus, Science Citation Index Expanded, BIOSIS Previews and Medicus/MEDLINE/PubMed, Journal Citation Reports gives the journal an Impact factor of 5.168. Oncotarget has an online archive of its articles, however, each issue can also be printed on special demand.The term “oncotarget” covers all of the molecules, cellular functions and pathways common in cancer and aging, cancer cells and microbes, lymphocytes and neurons as well as neurodegeneration and atherosclerosis. Oncotarget’s online popularity is continually rising. This is due in part to its insightful, punctual, constructive, multiple peer-review process. This helps authors to increase their research’s impact.
The mission of the multidisciplinary journal is to make the results of scientific research being cone worldwide rapidly and widely available. Oncotarget also aims to eliminate the barriers between specialties and link the different areas of biomedical science. The publication also fosters applications of both basic and clinical science to help fight disease.Guided by the leadership of some of the world’s most prominent scientists, Oncotarget helps all researchers to be able to contribute to scientific progress. The ultimate goal is life without disease. The scientific community has so readily embraced the publication that Oncotarget has now launched sections on topics beyond oncology. The journal now accepts papers on Aging, Autophagy, Cardiology, Cell Biology, Cell Diseases, Chromosome, Endocrinology, Immunology, Metabolism, Neuroscience, Pathology, Pharmacology, Stem Cell and many other areas.
Oncotarget editorial board members Nobel prize winner Andrew Schally and former Cancer Research editor-in-chief Carlo M. Croce have had a combined 37 papers published in Oncotarget. Since 2013, Alexander Varshavsky, Bert Vogelstein, Stephen J. Elledge and Michael N. Hall, all members of Oncotarget/Oncoscience/Gerotarget, have won the Breakthrough Prize, the highest prize for scientific research.The authors give permission for anyone to copy, download, distribute, reprint, reuse or modify any articles that is published in Oncotarget. However, the original authors of the articles as well as its source must be properly cited. This policy is designed to aid in the dissemination of the information contained in the publication. This helps to give as many people as possible the opportunity to learn from the material.